Baicalin inhibits the replication of the hepatitis B virus by targeting TRIM25

10.1016/j.jtcme.2023.05.009

Xixi Fan；Fei Wang；Hongxiao Song；Fengchao Xu；Xiaolu Li；Qi Wei；Bingxin Lei；Zhongnan Wang；Yue Wang；Guangyun Tan

HBV ； Baicalin ； TRIIM25 ； IFIT3

Journal of Traditional and Complementary Medicine

13卷6期（2023 / 11 / 01）

561 - 567

英文

Objective: Baicalin, which is a key bioactive constituent obtained from Scutellaria baicalensis, has been utilized in traditional Chinese medicine for many centuries. Although it has been reported that Baicalin (BA) can inhibit the replication of the Hepatitis B virus (HBV), the exact mechanism behind this process remains unclear. Interferon-stimulated genes (ISGs) are crucial in the process of antiviral defense. We aim to investigate whether BA can regulate the expression of ISGs, and thereby potentially modulate the replication of HBV. Methods: The study involved the use of CRISPR/Cas9 technology to perform knockout experiments on TRIM25 and IFIT3 genes. The expression of these genes was confirmed through techniques such as immunoblotting or Q-PCR. The levels of HBsAg and HBeAg were measured using ELISA, and the expression of interferon-stimulated genes was detected using a luciferase assay. Results: It is interesting to note that several ISGs belonging to the TRIM family, including TRIM5, TRIM25, and TRIM14, were induced after BA treatment. On the other hand, members of the IFIT family were reduced by BA stimulation. Additionally, BA-mediated HBV inhibition was found to be significantly restored in HepG2 cells where TRIM25 was knocked out. Additional research into the mechanism of action of BA found that prolonged treatment with BA activated the JAK/STAT signaling pathway while simultaneously inhibiting the NF-kB pathway. Conclusion: The findings of our study indicate that TRIM25 has a significant impact on the regulation of HBV replication following BA treatment, providing additional insight into the mechanisms by which BA exerts its antiviral effects.

1. Abbas, YM(2017).Structure of human IFIT1 with capped RNA reveals adaptable mRNA binding and mechanisms for sensing N1 and N2 ribose 2'-O methylations.Proc Natl Acad Sci U S A,114(11),E2106-E2115.
2. Bray, NL(2016).Near-optimal probabilistic RNA-seq quantification.Nat Bio-technol,34(5),525-527.
3. Chen, W(2016).Cancer statistics in China, 2015.CA A Cancer J Clin,66(2),115-132.
4. Choi, YJ,Bowman, JW,Jung, JU(2018).Talented Duo A. IFIT1 and IFIT3 patrol viral RNA caps.Immunity,48(3),474-476.
5. Chow, KT,Gale, M, Jr(2015).SnapShot: interferon signaling.Cell,163(7),1808-1808e1.
6. Crow, YJ,Stetson, DB(2022).The type I interferonopathies: 10 years on.Nat Rev Immunol,22(8),471-483.
7. Dinda, B(2017).Therapeutic potentials of baicalin and its aglycone, baicalein against inflammatory disorders.Eur J Med Chem,131,68-80.
8. Gack, MU(2007).TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity.Nature,446(7138),916-920.
9. Hsiao, WL,Liu, L(2010).The role of traditional Chinese herbal medicines in cancer therapy–from TCM theory to mechanistic insights.Planta Med,76(11),1118-1131.
10. Ivashkiv, LB,Donlin, LT(2014).Regulation of type I interferon responses.Nat Rev Immunol,14(1),36-49.
11. Ji, W(2019).Baicalin protects against ethanol-induced chronic gastritis in rats by inhibiting Akt/NF-kappaB pathway.Life Sci,239,117064.
12. Johnson, B(2018).Human IFIT3 modulates IFIT1 RNA binding specificity and protein stability.Immunity,48(3),487-499e5.
13. Koepke, L,Gack, MU,Sparrer, KM(2021).The antiviral activities of TRIM proteins.Curr Opin Microbiol,59,50-57.
14. Lin, FC,Young, HA(2014).Interferons: success in anti-viral immunotherapy.Cytokine Growth Factor Rev,25(4),369-376.
15. Luo, Y(2019).Application of Chinese medicine in acute and critical medical conditions.Am J Chin Med,47(6),1223-1235.
16. Martinez Medina, JJ(2017).Antioxidant and anticancer effects and bioavailability studies of the flavonoid baicalin and its oxidovanadium(IV) complex.J Inorg Biochem,166,150-161.
17. Martin-Vicente, M(2017).TRIM25 in the regulation of the antiviral innate immunity.Front Immunol,8,1187.
18. Mutimer, DJ,Lok, A(2012).Management of HBV- and HCV-induced end stage liver disease.Gut,61(Suppl 1),i59-i67.
19. Park, A,Iwasaki, A(2020).Type I and type III interferons - induction, signaling, evasion, and application to combat COVID-19.Cell Host Microbe,27(6),870-878.
20. Qiu, G(2020).Interpretation of guidelines for the diagnosis and treatment of primary liver cancer (2019 edition) in China.Glob Health Med,2(5),306-311.
21. Sankararaman, S(2022).Role of traditional Chinese herbal medicines in functional gastrointestinal and motility disorders.Curr Gastroenterol Rep,24(3),43-51.
22. Shao, M(2021).New insights into the effects of individual Chinese herbal medicines on chronic Kidney disease.Front Pharmacol,12,774414.
23. Stremlau, M(2004).The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys.Nature,427(6977),848-853.
24. Tan, G(2012).NF-kappaB-dependent microRNA-125b up-regulation promotes cell survival by targeting p38alpha upon ultraviolet radiation.J Biol Chem,287(39),33036-33047.
25. Tan, G(2018).When hepatitis B virus meets interferons.Front Microbiol,9,1611.
26. Tan, G(2019).Type-I-IFN-Stimulated gene TRIM5gamma inhibits HBV replication by promoting HBx degradation.Cell Rep,29(11),3551-3563e3.
27. Tan, G(2018).Identification of TRIM14 as a type I IFN-stimulated gene controlling hepatitis B virus replication by targeting HBx.Front Immunol,9,1872.
28. Tan, G(2018).Type I IFN augments IL-27-dependent TRIM25 expression to inhibit HBV replication.Cell Mol Immunol,15(3),272-281.
29. Tsounis, EP(2021).Toward a new era of hepatitis B virus therapeutics: the pursuit of a functional cure.World J Gastroenterol,27(21),2727-2757.
30. Wong, GLH,Gane, E,Lok, ASF(2022).How to achieve functional cure of HBV: stopping NUCs, adding interferon or new drug development?.J Hepatol,76(6),1249-1262.
31. Xia, C(2020).Baicalin down-regulating hepatitis B virus transcription depends on the liver-specific HNF4alpha-HNF1alpha axis.Toxicol Appl Pharmacol,403,115131.
32. Xu, F(2019).Type III interferon-induced CBFbeta inhibits HBV replication by hijacking HBx.Cell Mol Immunol,16(4),357-366.
33. Xu, F(2019).NF-kappaB-Dependent IFIT3 induction by HBx promotes hepatitis B virus replication.Front Microbiol,10,2382.
34. Yang, Z(2022).ALKBH5 regulates STAT3 activity to affect the proliferation and tumorigenicity of osteosarcoma via an m6A-YTHDF2-dependent manner.EBioMedicine,80,104019.
35. Zhao, F(2021).The functions of hepatitis B virus encoding proteins: viral persistence and liver pathogenesis.Front Immunol,12,691766.
36. Zhao, Z(2021).Prevention and treatment of COVID-19 using Traditional Chinese Medicine: a review.Phytomedicine,85,153308.
37. Zhou, C(2020).SLFN11 inhibits hepatocellular carcinoma tumorigenesis and metastasis by targeting RPS4X via mTOR pathway.Theranostics,10(10),4627-4643.
38. Zhou, J(2018).Guidelines for diagnosis and treatment of primary liver cancer in China (2017 edition).Liver Cancer,7(3),235-260.